Medicus Pharma Ltd.

For the period ended Nov 4, 2026. Filed Nov 4, 2026.

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Nov 4, 2026 · Filed Nov 4, 2026

MDCX$1.87+2.2%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

EX-99.2 · Topics will include:

Topics will include:

Financial performance of the Company and overview of the business outlook
Rationale for entering into the CD228V Co-development and Licensing agreement with Pfizer
Proposed SkinJect Business Combination and Concurrent Financing LOI
Development and partnership outlook for the Teverelix Program

Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can participate by dialing 1-833-890-6070 (U.S./Canada) or 1-412-504-9736 (international). A webcast of the call can be accessed here.

-1-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.